SG10201703533VA - Tricyclic fused thiophene derivatives as jak inhibitors - Google Patents

Tricyclic fused thiophene derivatives as jak inhibitors

Info

Publication number
SG10201703533VA
SG10201703533VA SG10201703533VA SG10201703533VA SG10201703533VA SG 10201703533V A SG10201703533V A SG 10201703533VA SG 10201703533V A SG10201703533V A SG 10201703533VA SG 10201703533V A SG10201703533V A SG 10201703533VA SG 10201703533V A SG10201703533V A SG 10201703533VA
Authority
SG
Singapore
Prior art keywords
jak inhibitors
thiophene derivatives
tricyclic fused
fused thiophene
tricyclic
Prior art date
Application number
SG10201703533VA
Inventor
Yun-Long Li
Wenyu Zhu
Song Mei
Joseph Glenn
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49578588&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201703533V(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of SG10201703533VA publication Critical patent/SG10201703533VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG10201703533VA 2012-11-01 2013-10-31 Tricyclic fused thiophene derivatives as jak inhibitors SG10201703533VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261721308P 2012-11-01 2012-11-01
US201361783850P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
SG10201703533VA true SG10201703533VA (en) 2017-06-29

Family

ID=49578588

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201703533VA SG10201703533VA (en) 2012-11-01 2013-10-31 Tricyclic fused thiophene derivatives as jak inhibitors
SG11201503141TA SG11201503141TA (en) 2012-11-01 2013-10-31 Tricyclic fused thiophene derivatives as jak inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201503141TA SG11201503141TA (en) 2012-11-01 2013-10-31 Tricyclic fused thiophene derivatives as jak inhibitors

Country Status (22)

Country Link
US (6) US9181271B2 (en)
EP (1) EP2917221A1 (en)
JP (2) JP6359546B2 (en)
KR (1) KR20150074193A (en)
CN (2) CN104918945B (en)
AR (1) AR093308A1 (en)
AU (2) AU2013337824B2 (en)
BR (1) BR112015009942A2 (en)
CA (1) CA2888816A1 (en)
CL (1) CL2015001160A1 (en)
CR (1) CR20150255A (en)
EA (1) EA031882B1 (en)
HK (1) HK1214823A1 (en)
IL (2) IL238410B (en)
MX (1) MX2015005428A (en)
NZ (1) NZ707495A (en)
PE (1) PE20151141A1 (en)
PH (1) PH12015500963B1 (en)
SG (2) SG10201703533VA (en)
TW (1) TWI646099B (en)
UA (1) UA117572C2 (en)
WO (1) WO2014071031A1 (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2612196T3 (en) 2005-12-13 2017-05-12 Incyte Holdings Corporation Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines substituted with heteroaryl as Janus kinase inhibitors
EP2173752B2 (en) 2007-06-13 2022-07-13 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
TWI484962B (en) 2009-05-22 2015-05-21 Incyte Corp 3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)octane-or heptane-nitrile as jak inhibitors
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
AU2010273816B2 (en) 2009-06-29 2015-07-09 Incyte Holdings Corporation Pyrimidinones as PI3K inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
KR102354472B1 (en) 2010-03-10 2022-01-21 인사이트 홀딩스 코포레이션 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP2574168B9 (en) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
JP5876146B2 (en) 2011-06-20 2016-03-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Azetidinylphenyl, pyridyl, or pyrazinylcarboxamide derivatives as JAK inhibitors
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
AR087760A1 (en) 2011-09-02 2014-04-16 Incyte Corp HETEROCICLILAMINAS AS PI3K INHIBITORS
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
AR090548A1 (en) 2012-04-02 2014-11-19 Incyte Corp BICYCLIC AZAHETEROCICLOBENCILAMINS AS PI3K INHIBITORS
AR091079A1 (en) 2012-05-18 2014-12-30 Incyte Corp DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
SG10201703533VA (en) * 2012-11-01 2017-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
HUE055894T2 (en) 2012-11-15 2021-12-28 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
KR102403306B1 (en) 2013-01-15 2022-06-02 인사이트 홀딩스 코포레이션 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
PE20151902A1 (en) 2013-03-06 2015-12-26 Incyte Corp PROCESS AND INTERMEDIATES TO MAKE A JAK INHIBITOR
JP6294953B2 (en) 2013-03-14 2018-03-14 ヤンセン ファーマシューティカ エヌ．ベー． P2X7 modulator
EP2970304B1 (en) 2013-03-14 2018-08-15 Janssen Pharmaceutica NV P2x7 modulators
JO3773B1 (en) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv P2x7 modulators
JO3509B1 (en) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv P2x7 modulators
CN108707140B (en) 2013-03-14 2022-07-22 勃林格殷格翰国际有限公司 Protease C inhibitors
SI3527263T1 (en) 2013-05-17 2021-05-31 Incyte Corporation Bipyrazole derivatives as jak inhibitors
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
PL3110409T3 (en) * 2014-02-28 2018-12-31 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
UA119767C2 (en) 2014-04-08 2019-08-12 Інсайт Корпорейшн Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
TW201625643A (en) * 2014-04-30 2016-07-16 英塞特公司 Processes of preparing a JAK1 inhibitor and new forms thereto
WO2015184305A1 (en) * 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
ES2714048T3 (en) 2014-09-12 2019-05-24 Janssen Pharmaceutica Nv P2X7 modulators
EA031376B1 (en) 2014-09-12 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Spirocyclic inhibitors of cathepsin c
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
PT3262046T (en) 2015-02-27 2020-12-24 Incyte Corp Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
US9708333B2 (en) 2015-08-12 2017-07-18 Incyte Corporation Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
AR105967A1 (en) 2015-09-09 2017-11-29 Incyte Corp SALTS OF A PIM QUINASA INHIBITOR
TW201718546A (en) 2015-10-02 2017-06-01 英塞特公司 Heterocyclic compounds useful as PIM kinase inhibitors
PL3371190T3 (en) 2015-11-06 2022-11-07 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
ES2833955T3 (en) 2016-01-05 2021-06-16 Incyte Corp Pyridines substituted with pyrazole / imidazole as PI3K-Gamma inhibitors
SG10202009423QA (en) 2016-03-28 2020-11-27 Incyte Corp Pyrrolotriazine compounds as tam inhibitors
WO2017223414A1 (en) 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
PT3509591T (en) * 2016-10-03 2021-12-27 Highlightll Pharmaceutical Hainan Co Ltd Novel jak1 selective inhibitors and uses thereof
EP3568396B1 (en) 2017-01-11 2020-11-11 Leo Pharma A/S Novel amino-imidazopyridine derivatives as janus kinase inhibitors and pharmaceutical use thereof
TWI821200B (en) 2017-09-27 2023-11-11 美商英塞特公司 Salts of tam inhibitors
WO2019079469A1 (en) 2017-10-18 2019-04-25 Incyte Corporation Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
DK3746429T3 (en) 2018-01-30 2022-05-02 Incyte Corp PROCEDURES FOR THE PREPARATION OF (1- (3-FLUORO-2- (TRIFLUOROMETHYL) ISONICOTINYL) PIPERIDIN-4-ON)
BR122023022189A2 (en) 2018-02-16 2024-02-20 Incyte Corporation USES OF JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS
MA52655A (en) 2018-03-30 2021-02-17 Incyte Corp BIOMARKERS FOR INFLAMMATORY SKIN DISEASE
IL277538B1 (en) * 2018-03-30 2024-05-01 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
WO2019200030A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
WO2020007698A1 (en) 2018-07-06 2020-01-09 Leo Pharma A/S Novel amino-imidazopyrimidine derivatives as janus kinase inhibitors and pharmaceutical use thereof
PT3847175T (en) 2018-09-05 2024-04-16 Incyte Corp Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
TW202035409A (en) 2018-09-28 2020-10-01 比利時商健生藥品公司 Monoacylglycerol lipase modulators
JP7482116B2 (en) 2018-09-28 2024-05-13 ヤンセン ファーマシューティカ エヌ．ベー． Monoacylglycerol lipase regulators
KR20210109522A (en) 2018-10-31 2021-09-06 인사이트 코포레이션 Combination Therapy for Treatment of Blood Disorders
KR20210116487A (en) 2018-12-19 2021-09-27 인사이트 코포레이션 JAK1 pathway inhibitors for the treatment of gastrointestinal diseases
US11406640B2 (en) 2019-03-05 2022-08-09 Incyte Corporation JAK1 pathway inhibitors for the treatment of chronic lung allograft dysfunction
JP2022526301A (en) 2019-03-19 2022-05-24 インサイト・コーポレイション Biomarker of vitiligo vulgaris
CA3142625A1 (en) * 2019-06-06 2020-12-10 Highlightll Pharmaceutical (Hainan) Co., Ltd Synthesis method of furoimidazopyridine compound, crystal form of furoimidazopyridine compound, and crystal form of salt thereof
MX2021014320A (en) * 2019-06-06 2022-02-21 Highlightll Pharmaceutical Hainan Co Ltd Method for synthesizing furoimidazopyridine compound, polymorphic substance and polymorphic substance of salt.
KR20220075386A (en) 2019-09-30 2022-06-08 얀센 파마슈티카 엔.브이. Radiolabeled MGL PET Ligand
WO2021072098A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
WO2021072116A1 (en) 2019-10-10 2021-04-15 Incyte Corporation Biomarkers for graft-versus-host disease
WO2021076124A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
JP2023509452A (en) 2020-01-03 2023-03-08 バーグ エルエルシー Polycyclic Amides as UBE2K Modulators to Treat Cancer
CN111297870B (en) * 2020-03-20 2021-03-26 中国医学科学院医药生物技术研究所 Application of nitrobenzoic acid compounds in preparation of drugs for treating tumors
CA3176946A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
MX2022015221A (en) 2020-06-02 2023-03-08 Incyte Corp Processes of preparing a jak1 inhibitor.
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
IL303410A (en) 2020-12-04 2023-08-01 Incyte Corp Jak inhibitor with a vitamin d analog for treatment of skin diseases
IL303238A (en) 2020-12-08 2023-07-01 Incyte Corp Jak1 pathway inhibitors for the treatment of vitiligo
US11918581B2 (en) 2021-01-11 2024-03-05 Incyte Corporation Combination therapy comprising JAK pathway inhibitor and rock inhibitor
IL308216A (en) 2021-05-03 2024-01-01 Incyte Corp Jak1 pathway inhibitors for the treatment of prurigo nodularis
WO2023283345A1 (en) 2021-07-07 2023-01-12 Incyte Corporation Anti-b7-h4 antibodies and uses thereof
US20230272055A1 (en) 2021-12-08 2023-08-31 Incyte Corporation Anti-mutant calreticulin (calr) antibodies and uses thereof
WO2024030600A1 (en) 2022-08-05 2024-02-08 Incyte Corporation Treatment of urticaria using jak inhibitors

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1306260C (en) * 1985-10-18 1992-08-11 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
JP2513001B2 (en) 1988-11-01 1996-07-03 山川薬品工業株式会社 Method for racemization of optically active tetrahydrofuran-2-carboxylic acid
JPH02225463A (en) 1989-02-27 1990-09-07 Nissan Chem Ind Ltd Racemization of n-acetyl-indoline-2-carboxylic acid ester
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
FR2695126B1 (en) 1992-08-27 1994-11-10 Sanofi Elf Thienyl or pyrrolyl carboxylic acid derivatives, their preparation and medicaments containing them.
JP3178301B2 (en) 1994-08-08 2001-06-18 東レ株式会社 Process for producing racemic aliphatic heterocyclic carboxylate
EP0727217A3 (en) 1995-02-10 1997-01-15 Suntory Ltd Pharmaceutical composition containing god-type ellagitannin as active ingredient
US6025366A (en) * 1998-04-02 2000-02-15 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
DE69942097D1 (en) 1998-08-11 2010-04-15 Novartis Ag ISOCHINOLINE DERIVATIVES WITH ANGIOGENESIS-HEMMENDER EFFECT
JP2000119271A (en) * 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
PT1294358E (en) 2000-06-28 2004-12-31 Smithkline Beecham Plc MOORING PROCESS BY HUMIDITY
WO2002016370A1 (en) * 2000-08-22 2002-02-28 Hokuriku Seiyaku Co., Ltd. 1h-imidazopyridine derivatives
JP2003002890A (en) 2000-08-22 2003-01-08 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
CA2466243A1 (en) 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
KR20090087139A (en) 2001-10-30 2009-08-14 노파르티스 아게 Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (en) 2002-11-15 2005-06-08 Vertex Pharma USEFUL DIAMINOTRIAZOLS AS INHIBITORS OF PROTEINQUINASES
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP4374222B2 (en) 2003-09-01 2009-12-02 Ｈｏｙａ株式会社 Variable magnification optical system
PE20050952A1 (en) 2003-09-24 2005-12-19 Novartis Ag DERIVATIVES OF ISOQUINOLINE AS INHIBITORS OF B-RAF
WO2005105814A1 (en) 2004-04-28 2005-11-10 Incyte Corporation Tetracyclic inhibitors of janus kinases
MY144044A (en) 2004-06-10 2011-07-29 Irm Llc Compounds and compositions as protein kinase inhibitors
KR20070085433A (en) 2004-11-24 2007-08-27 노파르티스 아게 Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AR054416A1 (en) 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
WO2007044050A2 (en) 2005-02-04 2007-04-19 Bristol-Myers Squibb Company 1h-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US20070149506A1 (en) 2005-09-22 2007-06-28 Arvanitis Argyrios G Azepine inhibitors of Janus kinases
US20130137681A1 (en) 2005-12-13 2013-05-30 Incyte Corporation HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
ES2612196T3 (en) 2005-12-13 2017-05-12 Incyte Holdings Corporation Pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines substituted with heteroaryl as Janus kinase inhibitors
CN101516875A (en) * 2006-07-21 2009-08-26 沃泰克斯药物股份有限公司 CGRP receptor antagonists
AU2007338793B2 (en) * 2006-12-20 2012-05-03 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
WO2008079965A1 (en) 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
EP2173752B2 (en) 2007-06-13 2022-07-13 Incyte Holdings Corporation Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2008001709A1 (en) 2007-06-13 2008-11-03 Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
BRPI0820544A2 (en) 2007-11-16 2015-06-16 Incyte Corp 4-pyrazolyl-n-arylpyrimidin-2-amines and pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
KR20120108042A (en) 2008-03-11 2012-10-04 인사이트 코포레이션 Azetidine and cyclobutane derivatives as jak inhibitors
CA2727928A1 (en) * 2008-06-18 2009-12-23 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
WO2009155551A1 (en) * 2008-06-20 2009-12-23 Genentech, Inc. Triazolopyridine jak inhibitor compounds and methods
CL2009001884A1 (en) 2008-10-02 2010-05-14 Incyte Holdings Corp Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
JOP20190230A1 (en) 2009-01-15 2017-06-16 Incyte Corp Processes for preparing jak inhibitors and related intermediate compounds
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
TWI484962B (en) 2009-05-22 2015-05-21 Incyte Corp 3-(4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-1h-pyrazol-1-yl)octane-or heptane-nitrile as jak inhibitors
JP5690823B2 (en) * 2009-07-08 2015-03-25 レオ ファーマ アクティーゼルスカブ Heterocyclic compounds as JAK receptors and protein tyrosine kinase inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2486041B1 (en) 2009-10-09 2013-08-14 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CA2781578A1 (en) * 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
US20110207754A1 (en) 2010-02-18 2011-08-25 Incyte Corporation Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
KR102354472B1 (en) 2010-03-10 2022-01-21 인사이트 홀딩스 코포레이션 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP2574168B9 (en) 2010-05-21 2016-10-05 Incyte Holdings Corporation Topical formulation for a jak inhibitor
WO2012068450A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
JP5917544B2 (en) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Heterocyclic substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CA2827673C (en) 2011-02-18 2020-10-27 Novartis Pharma Ag Mtor/jak inhibitor combination therapy
EP2684880B1 (en) 2011-03-10 2018-02-28 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivative
JP5876146B2 (en) 2011-06-20 2016-03-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Azetidinylphenyl, pyridyl, or pyrazinylcarboxamide derivatives as JAK inhibitors
WO2013007768A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
WO2013007765A1 (en) 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
AR091079A1 (en) 2012-05-18 2014-12-30 Incyte Corp DERIVATIVES OF PIRROLOPIRIMIDINA AND PIRROLOPIRIDINA REPLACED WITH PIPERIDINILCICLOBUTILO AS JAK INHIBITORS
SG10201703533VA (en) * 2012-11-01 2017-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
HUE055894T2 (en) 2012-11-15 2021-12-28 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
PE20151902A1 (en) 2013-03-06 2015-12-26 Incyte Corp PROCESS AND INTERMEDIATES TO MAKE A JAK INHIBITOR
SI3527263T1 (en) 2013-05-17 2021-05-31 Incyte Corporation Bipyrazole derivatives as jak inhibitors
EP3721873A1 (en) 2013-08-07 2020-10-14 Incyte Corporation Sustained release dosage forms for a jak1 inhibitor
SG11201601119XA (en) * 2013-08-20 2016-03-30 Incyte Corp Survival benefit in patients with solid tumors with elevated c-reactive protein levels
PL3110409T3 (en) 2014-02-28 2018-12-31 Incyte Corporation Jak1 inhibitors for the treatment of myelodysplastic syndromes
UA119767C2 (en) * 2014-04-08 2019-08-12 Інсайт Корпорейшн Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
TW201625643A (en) * 2014-04-30 2016-07-16 英塞特公司 Processes of preparing a JAK1 inhibitor and new forms thereto
WO2015184305A1 (en) * 2014-05-30 2015-12-03 Incyte Corporation TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10077277B2 (en) * 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US10053465B2 (en) * 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
BR122023022189A2 (en) * 2018-02-16 2024-02-20 Incyte Corporation USES OF JAK1 PATHWAY INHIBITORS FOR THE TREATMENT OF CYTOKINE-RELATED DISORDERS
IL277538B1 (en) * 2018-03-30 2024-05-01 Incyte Corp Treatment of hidradenitis suppurativa using jak inhibitors
MA52655A (en) * 2018-03-30 2021-02-17 Incyte Corp BIOMARKERS FOR INFLAMMATORY SKIN DISEASE
WO2019200030A1 (en) * 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
KR20210109522A (en) * 2018-10-31 2021-09-06 인사이트 코포레이션 Combination Therapy for Treatment of Blood Disorders
JP2022526301A (en) * 2019-03-19 2022-05-24 インサイト・コーポレイション Biomarker of vitiligo vulgaris

Also Published As

Publication number Publication date
US11161855B2 (en) 2021-11-02
US20140121198A1 (en) 2014-05-01
IL257066A (en) 2018-03-29
US20210387998A1 (en) 2021-12-16
CN104918945A (en) 2015-09-16
AU2018204090A1 (en) 2018-06-28
US20200040002A1 (en) 2020-02-06
IL238410B (en) 2018-02-28
CR20150255A (en) 2015-09-09
US11851442B2 (en) 2023-12-26
EA201590850A1 (en) 2015-09-30
WO2014071031A1 (en) 2014-05-08
UA117572C2 (en) 2018-08-27
EA031882B1 (en) 2019-03-29
US20180148460A1 (en) 2018-05-31
TWI646099B (en) 2019-01-01
JP2015535288A (en) 2015-12-10
MX2015005428A (en) 2015-07-21
HK1214823A1 (en) 2016-08-05
BR112015009942A2 (en) 2017-07-11
JP6359546B2 (en) 2018-07-18
PE20151141A1 (en) 2015-08-06
AU2013337824B2 (en) 2018-03-08
JP2018141020A (en) 2018-09-13
TW201422624A (en) 2014-06-16
PH12015500963A1 (en) 2015-08-17
CA2888816A1 (en) 2014-05-08
EP2917221A1 (en) 2015-09-16
US20160015695A1 (en) 2016-01-21
AR093308A1 (en) 2015-05-27
KR20150074193A (en) 2015-07-01
NZ707495A (en) 2019-01-25
CL2015001160A1 (en) 2015-08-28
US9777017B2 (en) 2017-10-03
PH12015500963B1 (en) 2015-08-17
US10370387B2 (en) 2019-08-06
US20160024109A1 (en) 2016-01-28
SG11201503141TA (en) 2015-06-29
CN104918945B (en) 2018-01-05
US9908895B2 (en) 2018-03-06
CN107936039A (en) 2018-04-20
US9181271B2 (en) 2015-11-10
AU2013337824A1 (en) 2015-05-14
IL238410A0 (en) 2015-06-30

Similar Documents

Publication Publication Date Title
IL257066A (en) Tricyclic fused thiophene derivatives as jak inhibitors
HUS2200040I1 (en) Benzimidazole-proline derivatives
IL245309B (en) Tricyclic heterocyclic compounds as jak inhibitors
HK1206722A1 (en) New bicyclic derivatives
IL227252A0 (en) Fused aminodihydrothiazine derivatives
HK1206723A1 (en) Thienopyrimidines
EP2862853A4 (en) Fused heterocyclic compound
EP2865671A4 (en) Fused heterocyclic compound
EP2857396A4 (en) Fused heterocyclic compound
EP2857397A4 (en) Fused heterocyclic compound
GB201101140D0 (en) Fused aminodihydrothiazine derivatives
HK1205740A1 (en) Pyrrolotriazinone derivatives
HK1205508A1 (en) New bicyclicpyridine derivatives
EP2865672A4 (en) Fused heterocyclic compound
EP2824106A4 (en) Tricyclic compound
AP2015008347A0 (en) Oxazolidin-2-one-pyrimidine derivatives
PL2838883T3 (en) New phenyl-tetrahydroisoquinoline derivatives
HK1208997A1 (en) Novel cabergoline derivatives
SG11201404325VA (en) Pyrimidooxazocine derivatives as mtor - inhibitors
GB201215033D0 (en) Diazepinone derivatives
GB201219689D0 (en) Novel Heteroaromatic derivatives I
GB201119592D0 (en) Novel heteroaromatic Derivatives I
GB201100183D0 (en) Fused aminodihydropyrimidone derivatives
AU2012177V (en) Daispanfunk Pandorea jasminoides